Pfizer’s 14+% Rally This Week Weakens Case for Put Options: Options Chatter
$Pfizer (PFE.US)$’s 14.5% share price rally so far this week is weakening the case for put options that give their holders the right to sell the stock as the drugmaker's outlook improves.
The stock jumped 6.8% Wednesday, on course for its biggest weekly advance in almost four years, after the company agreed to participate in TrumpRx.gov, a direct-to-customer purchasing platform, which will offer an average of 50% discount on some of its medicines.
Under the agreement with the Trump administration, Pfizer said yesterday that the company won’t have to face tariffs, as it invests in manufacturing in the U.S. The drugmaker earmarked $70 billion for research, development and capital projects over the next few years, adding to the $83 billion it spent in biotech innovation from 2018 through 2024, it said in a press release.
That news came days after the company announced an agreement to buy $Metsera(Delisted) (MTSR.US)$, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases.
“We think this voluntary agreement fits well with our current forecast, with most of the long-term policy pressure coming from rising tax rates as more of the firm's manufacturing moves to the U.S.,” Morningstar analyst Karen Andersen, who has a buy rating on the stock, said in a note to clients Wednesday. “We think this announcement could allow Pfizer—and investors—to refocus on pipeline advancement, and we point to Metsera and Seagen as two key acquisitions that could result in long-term growth opportunities for this undervalued firm.”
A total of 858,540 call options that give their holder the right to buy Pfizer shares at a specified strike price changed hands Wednesday, more than 7X the 20-day average volume. Put options, which give their holders the right to sell the stock saw volume of about 149,960 contracts. While that's up from a 20-day average of 49,486, the put-call ratio fell to 0.17, the lowest since July.
Pfizer's total options volume reached 1.01 million, landing it in fourth slot for the most active stock options, behind $Tesla (TSLA.US)$'s 2.48 million contracts, $NVIDIA (NVDA.US)$'s 2.47 million and $Intel (INTC.US)$'s 1.17 million.
Call options that give their holder the right to buy the stock at $26.50 in two days attracted the heaviest trading activity, with volume jumping five-fold to 40,110, 10X open interest as the stock price climb above that strike price, putting the contract well in the money.
CFRA analyst Sel Hardy raised her price target on the stock to $30, from $28, as she viewed the grace period that Pfizer got from pharmaceutical tariffs by the Trump administration as “positive.”
She now expects the company’s 20226 earnings rising to $3.21 per share, from a previous outlook of $3.06.
Share your thoughts on Pfizer in the comments section. Do you expect the share price rally to gain steam? Let your voice be heard by voting below. And if you want to read more columns on these short positions or read more on the movement in the options market like this one on Tilray, or this one on Amazon, follow me here.
Disclaimer: Options trading entails significant risk and is not appropriate for all customers. It is important that investors read the Characteristics and Risks of Standardized Options before engaging in any options trading strategies. Opening new options positions close to or on their expiration date comes with substantial risk of losses for reasons that include potential volatility of the underlying security and limited time to expiration. Options transactions are often complex and may involve the potential of losing the entire investment in a relatively short period. Certain complex option strategies carry additional risk, including potential losses that may exceed the original investment amount. If applicable, supporting documentation for any claims will be furnished upon request.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Luzi Ann Santos
Moomoo Senior News and Community Manager
Former editor at Bloomberg, ex-commentary editor at Lazard. Posts aren’t investment advice. Views are just mine.
15K
Followers
20
Following
39K
Visitors
Follow
Market Insights
Hot Topics Hot Topics
Trump's 'Taco deal' sparks market rebound : Market rebound sustainable ?
1. If tariffs pause, which sectors benefit first? 2. Trump's "threat-compromise" cycle normalizes—how to hedge across assets?
Moo Options Explorer
Apr 7 17:28
Weekly roundup: Tariff turmoil and recession fears dominate
Moo Options Explorer
Mar 31 17:01
Weekly roundup: Tariff concerns and Tesla’s rollercoaster ride
webguybob : I'm pfine with all of that.
DaddyBenjamin : Pfizer is blood money. I feel they are supposed to be a "Health" company but have shown over the last years they will sidestep that for profit. They will never see a dime of investment from me.